Notícias

Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.3% year on year to $265.8 million. On top of that, next quarter’s revenue guidance ($302 million at the midpoint) was surprisingly good and 14.9% above what analysts were expecting. Its non-GAAP profit of $0.89 per share was 7.2% above analysts’ consensus estimates.

Novanta (NasdaqGS:NOVT) has closed its acquisition of RiverPoint Medical, the largest deal in the company's history. The transaction expands Novanta's exposure to medical end markets and is expected to be immediately accretive to revenue growth and margins. Management is accelerating a manufacturing restructuring plan alongside the RiverPoint integration, with potential long-term effects on efficiency and profitability. For investors watching how medical technology companies scale up and...